Division of Imaging Sciences, King's College London BHF Centre of Excellence, NIHR Biomedical Research Centre, London SE1 7EH, UK.
Eur Heart J. 2010 Sep;31(18):2209-15. doi: 10.1093/eurheartj/ehq256. Epub 2010 Aug 12.
Coronary revascularization has been a cornerstone of the management of patients with coronary artery disease (CAD) for many years. Both coronary artery bypass grafting and percutaneous coronary intervention have evolved and improved over time such that increasingly complex and challenging cases can now be tackled with a high degree of procedural success. In parallel with this, there have been major advances in medical therapy for CAD. Consequently, one of the main decisions in the contemporary management of stable CAD concerns which patients and lesions should be revascularized. This is particularly true for patients with complex disease such as multivessel disease or those with left ventricular impairment. Such patients will potentially benefit the most but are also at highest risk of complications and it is therefore important that they are carefully selected. Recent major trials have challenged the conventional view that consideration of coronary anatomy alone is sufficient in this decision-making. An accumulating body of evidence underscores the importance of functional investigations when assessing the potential benefits of revascularization in these complex patients. In parallel with these developments, cardiac magnetic resonance (CMR) has matured into a robust technology that is able to measure many of the parameters required to accurately characterize these patients. This article will review the importance of myocardial viability and ischaemia when selecting patients with stable CAD for revascularization, the use of CMR imaging for assessing this pathophysiology, and planning complex revascularization, and finally give an outlook on how CMR may help address some important outstanding clinical questions.
冠状动脉血运重建术多年来一直是冠心病(CAD)患者治疗的基石。冠状动脉旁路移植术和经皮冠状动脉介入治疗都随着时间的推移而发展和改进,以至于现在可以用高度的手术成功率来解决越来越复杂和具有挑战性的病例。与此同时,CAD 的药物治疗也取得了重大进展。因此,在 CAD 的现代治疗中,一个主要决策是哪些患者和病变应该进行血运重建。对于患有多血管疾病或左心室功能障碍等复杂疾病的患者来说,这一点尤其正确。这些患者可能受益最大,但并发症风险也最高,因此仔细选择患者非常重要。最近的大型试验挑战了仅考虑冠状动脉解剖结构就足以做出这一决策的传统观点。越来越多的证据强调了在评估这些复杂患者血运重建潜在益处时进行功能研究的重要性。与这些发展并行的是,心脏磁共振(CMR)已经成熟为一种强大的技术,能够测量许多准确描述这些患者所需的参数。本文将回顾在选择稳定 CAD 患者进行血运重建时心肌存活和缺血的重要性,CMR 成像在评估这种病理生理学和规划复杂血运重建中的应用,并展望 CMR 如何帮助解决一些重要的临床遗留问题。